Drug Trial Radar · NCT05411861
Post-Operative Pain and Opioid Reduction Trial After Bunionectomy
Last checked: Nov 19, 2026Latest source record: Jan 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Jun 14, 2022
Primary completion
Sep 26, 2022
Study completion Nov 7, 2022
Sponsor
- Lead sponsor
- Cali Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing bunionectomy.
Conditions
- Hallux Valgus and Bunion
Interventions
Analgesic Non NarcoticDrug
Injection of protocol-specified volume of local analgesic
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC72Time frame: 72 hours post-operative
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Arizona Research Center
Phoenix, Arizona
Trovare Clinical Research
Bakersfield, California
Jean Brown Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.